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doi:10.1016/j.jtcvs.2008.02.03882 The Journal of Thoracic and CardioObjective: This study was undertaken to examine the operative mortality and morbid-
ity and late outcomes in patients who required combined aortic root replacement with
mitral valve surgery.
Methods: These combined procedures were performed in 123 patients with a mean
age of 51 6 16 years; 67% were men. The aortic root pathology was an aneurysm
in 76 patients and other disorders in 47 patients. The mitral valve pathology was de-
generative disease in 62 patients and other diseases in 61 patients. Sixty-four patients
(52%) underwent previous cardiac surgery. The aortic valve was preserved in 21 pa-
tients, and the mitral valve was preserved in 67 patients; the remaining patients under-
went valve replacement. In addition, 57 patients underwent other procedures. The
mean follow-up was 4.9 6 4.3 years and complete.
Results: The operative mortality rate was 6.5% (8 patients), and late mortality was
9.7% (12 patients). Reexploration of the mediastinum for bleeding (15%) and implan-
tation of permanent pacemaker (18%) were the most common postoperative compli-
cations. Urgent surgery and functional class IV were predictors of operative mortality
by univariate analysis. Survival at 1, 5, and 10 years was 90.9% 6 2.6%, 86.1% 6
3.3%, and 79.3 6 4.9%, respectively. Six patients required reoperation. Freedom
from reoperation at 1, 5, and 10 years was 100%, 96.4% 6 2.5%, and 85.7% 6
6.4%, respectively. At the latest follow-up, 98 patients were alive and free from reop-
eration; 92 patients were in functional classes 1 and 2, and 88 patients were free from
any cardiac or valve-related complication.
Conclusion:Aortic root replacement combined with mitral valve surgery is a complex
operation associated with high morbidity, but the operative mortality is reasonably
low and the long-term outcomes are gratifying.
R
eplacement of the aortic root with valved conduits and replacement of the aor-
tic root with preservation of the native aortic cusps, such as in aortic valve-
sparing operations, are established surgical options to treat patients with aortic
root aneurysms and other disorders of the aortic root. Degenerative diseases are the
most common cause of aortic root aneurysm; consequently, a proportion of these
patients will have associated mitral regurgitation caused by mitral valve (MV)
prolapse.1,2 Thus, combined aortic root replacement (ARR) with MV surgery is not
a rare operation. Moreover, there are increasing numbers of patients who underwent
ARR and require reoperation for failed biologic valves or infective endocarditis
with aortic root abscess and involvement of the MV. Add coronary artery disease to
these patients, and the cardiac surgeon is faced with a serious technical challenge.3 Al-
though there are case reports on combinedARRwithMV surgery and reference ofMV
surgery in series of longitudinal outcomes of ARR,2,4-8 we could not find an article that
examined this issue in clinical cardiac surgery. This study is an analysis of the operative
mortality and morbidity and long-term results of combined ARR with MV surgery.
Patients and Methods
A review of our clinical database disclosed 123 consecutive patients who underwent ARR com-
bined with MV surgery from 1981 to July of 2007, although 97 operations were performedvascular Surgery c July 2008
David et al Surgery for Acquired Cardiovascular Disease
A
CDAbbreviations and Acronyms
ARR 5 aortic root replacement
MV 5 mitral valve
during the past decade. Our review ethics board approved this retro-
spective study. Table 1 shows the clinical profile of patients. Table 2
summarizes the pathology of the aortic root and MV. Table 3 shows
the operative data. Only 12 patients underwent emergency opera-
tions because of sepsis, shock, or acute type A aortic dissection.
All operations were performed via a median sternotomy and car-
diopulmonary bypass with mild hypothermia (32C–34C) except
in patients who required replacement of the transverse arch, in which
case deep hypothermia was used. Myocardial protection was pro-
vided with cold blood cardioplegia delivered directly into the coro-
nary arteries. Myocardial revascularization was performed first,
followed by the MV procedure and finally the ARR. The mitral an-
nulus had to be reconstructed with autologous or bovine pericar-
dium in 22 patients because of dystrophic calcification of the
mitral annulus (18 patients) or annular abscess (4 patients). All
patients who had reconstruction of the mitral annulus also had
MV replacement. MV repair was performed in all patients with de-
generative disease of the MV or isolated dilation of the mitral annu-
lus (67 patients). In patients who had previous aortic and MV
replacement, the MV was approached through the aortic root and
an incision in the dome of the left atrium.9,10 An aortic valve-sparing
procedure was feasible in 21 patients: 8 remodelings of the aortic
root and 13 reimplantations of the aortic valve. A Dacron graft
with a valve was used to replace the aortic root in 50 patients, and
a biologic root was used in 30 patients. The remaining 22 patients
had a destroyed aortic annulus, and a tubular Dacron graft was tai-
lored to fit in the annular defect and sutured directly to the interven-
tricular septum, the intervalvular fibrous body, or the sewing ring of
a prosthetic MV. Afterward, an aortic valve was implanted into this
graft, and the coronary arteries were reimplanted.10 Eighteen pa-
tients also required tricuspid valve annuloplasty.
Patients who had combined aortic valve sparing with MV repair
and those who had a tailored tubular Dacron graft to fit the abnormal
annulus were followed prospectively at annual intervals. The re-
maining patients were followed irregularly up to 2005, but all pa-
tients except 1 surviving patient were contacted in the first 8
months of 2007. The follow-up for this report was closed on Sep-
tember 1, 2007. The mean follow-up was 4.9 6 4.3 years (range,
0–16 years).
All data analyses were performed with SAS 8.1 Software (SAS
Institute, Cary, NC). Categoric variables were analyzed with the chi-
square or Fisher exact test and reported as frequencies or percent-
ages. All continuous variables were reported as mean 6 standard
deviation. The Kaplan–Meier method was used to calculate esti-
mates for long-term survival and freedom from reoperation. All pre-
operative variables with a univariate P value of less than .25 or those
with known biologic significance but failing to meet this critical
a level were submitted to the multivariable model for Cox regres-
sion analysis to determine the independent multivariable predictors
of operative and late death. Variable retention criteria in the model
were set at a P value of .05.The Journal of ThoResults
The operative mortality rate was 6.5% (8 patients). The
causes of operative mortality were low cardiac output syn-
drome in 5 patients, stroke in 1 patient, pneumonia in 1 pa-
tient, and ruptured abdominal aortic aneurysm in 1 patient.
The cause of low cardiac output syndrome was believed to
TABLE 1. Clinical profile of patients
No. of patients 123
Age (y)
Mean 6 SD 51.2 6 16.5
Range 17 to 80
Sex:
male 82 (67)
Electrocardiogram:
Sinus rhythm 86 (70)
Atrial fibrillation 31 (25)
Heart block/pacemaker 6 (5)
Associated diseases:
Diabetes 10 (8)
Hypertension 31 (25)
Hyperlipidemia 18 (15)
Chronic obstructive pulmonary disease 3
Renal failure/dialysis 3
Peripheral vascular disease 3
New York Heart Association functional
classification:
Class I 18 (15)
Class II 23 (19)
Class III 38 (31)
Class IV 44 (36)
Marfan syndrome 3
Previous cardiac surgery: 64 (52)
AVR 28 (23)
AVR 1 MVR or repair 22 (18)
ARR 5 (4)
AVR or repair 1 RAA 4 (3)
RAA 2
Repair of aortic valve 1 VSD 2
Repair of tetralogy of Fallot 1
Left ventricular ejection fraction:
.60% 40 (32)
40%–59% 58 (47)
20%–39% 23 (19)
,20% 2 (2)
Infective endocarditis:
Remote 14 (11)
Active 3 (2)
Abscess 7 (6)
Coronary artery disease 22 (18)
Tricuspid insufficiency 18 (15)
SD, Standard deviation; AVR, aortic valve replacement; ARR, aortic root re-
placement;MVR, mitral valve replacement; RAA, replacement of ascending
aorta; VSD, ventricular septal defect. Percentages are shown in parenthe-
ses.racic and Cardiovascular Surgery c Volume 136, Number 1 83
Surgery for Acquired Cardiovascular Disease David et al
A
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root graft in 1 patient, perioperative myocardial infarction
in 2 patients, and right ventricular failure in 2 patients (prob-
ably related to inadequate myocardial protection resulting
from a nondominant right coronary artery). Table 4 shows
the operative mortality in various subgroups of patients.
Only urgent surgery (P 5 .007) and preoperative functional
class IV were associated with increased mortality by univar-
iate analysis (P, .0001). The operative mortality in patients
who had previous cardiac surgery was higher than after first-
time surgery (9.4% vs 3.4%), but the difference did not reach
statistical significance (P 5 .178) because of sample size.
There were no predictors of operative death by multivariate
analysis.
TABLE 2. Aortic and mitral valve pathology
Aortic root pathology:
Degenerative aneurysm 71 (58)
Aortic dissection 5 (4)
Porcelain aorta 4 (3)
Failed aortic root homograft 6 (5)
Previous AVR with patch enlargement
of annulus
16 (13)
Aortic root/mitral annulus abscess 7 (6)
Small aortic annulus 5 (4)
$4 previous AVRs 7 (6)
Aortic stenosis with normal root* 2 (2)
Aortic valve pathology:
Normal aortic cusps 16 (15)
Failed aortic valve homograft 6 (5)
Failed aortic bioprosthetic valve 38 (31)
Failed mechanical valve 6 (5)
Dysfunctional bicuspid aortic valve 25 (20)
Annuloaortic ectasia 10 (8)
Degenerative calcific 5 (4)
Rheumatic 4 (3)
Other connective tissue disorder 11 (10)
Aortic valve lesion:
None 15 (12)
Stenotic 23 (19)
Insufficiency 68 (55)
Mixed 17 (14)
MV pathology:
Degenerative 55 (45)
Rheumatic 20 (16)
Dystrophic calcification of mitral annulus 18 (15)
Annular dilation 12 (10)
Prosthetic valve dysfunction 15 (12)
Failed MV repair 3 (2)
MV lesion:
Stenotic 8 (6)
Insufficiency 82 (67)
Mixed 33 (27)
AVR, Aortic valve replacement;MV, mitral valve. *Both patients underwent
the Ross procedure. Percentages are shown in parentheses.84 The Journal of Thoracic and Cardiovascular Surgery c JulyPostoperative complications were common. Reexplora-
tion of the chest for bleeding was performed in 18 patients.
The bleeding was caused by coagulopathy in 11 patients,
leaking anastomosis in 5 patients, a branch of a vein graft
in 1 patient, and the bed of the internal thoracic artery in 1 pa-
tient. Ninety-seven patients (79%) received blood transfu-
sions (5.6 6 5.3 units/patient), and 39 patients (32%)
received fresh-frozen plasma or platelets. Tranexaminic
acid was used in 69 patients, and aprotinin was used in 42 pa-
tients. There was no difference in the blood requirement or
reexploration rates between patients who received these 2
antifibrinolytic agents. Implantation of permanent transve-
nous pacemaker for heart block was necessary in 22 patients,
mostly after reoperation (18 patients). Four patients had
a stroke (3 intraoperatively and 1 postoperatively), and 1 pa-
tient died. Two patients had perioperative myocardial infarc-
tion and died. Four patients had intra-aortic balloon pumps
because of low cardiac output syndrome. One patient had
new-onset renal failure. The length of intensive care stay
and total hospital stay are shown in Table 3.
There were 12 late deaths: 3 cardiac related (congestive
heart failure in all 3), 4 valve related (1 due to anticoagulant-
related hemorrhage, 1 due to structural valve deterioration,
TABLE 3. Operative data
No. Patients
Aortic root procedure:
Aortic valve sparing 21 (17)
Ross procedure 2 (2)
Valved conduit 50 (41)
Custom conduit 1 valve 22 (18)
Aortic root homograft 9 (7)
Medtronic Freestyle bioprosthesis
(Medtronic Inc, Minneapolis, Minn)
19 (15)
Aortic valve implanted:
Mechanical 58 (47)
Tissue 44 (36)
MV procedure:
Reconstruction of the mitral annulus1MVR 22 (18)
MVR 34 (28)
MV repair 67 (54)
MV implanted:
Mechanical 36 (29)
Tissue 20 (16)
Pulmonary valve replacement 2 (2)
Tricuspid valve annuloplasty 18 (15)
Coronary artery bypass 22 (18)
Replacement of transverse aortic arch 15 (12)
Aortic clamping time (min 6 SD) 141 6 33
Cardiopulmonary bypass time (min 6 SD) 171 6 49
ICU length of stay (d 6 SD) 4.7 6 7.0
Hospital length of stay (d 6 SD) 12.6 6 11.7
MVR, Mitral valve replacement; MV, mitral valve; SD, standard deviation;
ICU, intensive care unit. Percentages are shown in parentheses.2008
David et al Surgery for Acquired Cardiovascular Disease
A
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survival at 1, 5, and 10 years was 90.8% 6 2.6%, 86.1% 6
3.3%, and 79.3% 6 4.9%, respectively. Figure 1 shows
the Kaplan–Meier estimates of survival in all patients. Six
TABLE 4. Operative mortality
Variable
Patients at
risk
Operative
deaths P value
Age
,51 y 54 2 (3.7)
51–69 y 50 4 (8)
.69 y 19 2 (10.5) .500
Sex:
Male 82 3 (3.7)
Female 41 5 (12.2) .070
Associated diseases:
Diabetes 8 2 (25) .071
Hypertension 31 3 (9.7) .407
Hyperlipidemia 18 1 (5.5) .859
COPD 3 1 (33) .056
Peripheral vascular disease 3 0 .643
Chronic renal failure 3 0 .643
Emergent/urgent surgery 12 3 (25) .007
Functional class IV 44 8 (18) .000
Active infective endocarditis 10 2 (20) .077
Ejection fraction , 40% 25 3 (12) .211
Previous cardiac surgery 64 6 (9.4) .178
Coronary artery bypass 22 2 (4.5) .681
Aortic valve:
Repaired 21 0
Replaced 102 8 (7.8) .184
MV:
Repaired 67 2 (2.9)
Replaced 56 6 (10.7) .083
COPD, Chronic obstructive pulmonary disease (with forced expiratory vol-
ume at 1 second of less than 1); MV, mitral valve. Percentages are shown
in parentheses.
Figure 1. Kaplan–Meier estimates of survival after combined ARR
and MV surgery.The Journal of Thopatients underwent reoperation for failure of aortic valve
sparing (remodeling of the aortic root) (2 patients), dehis-
cence of the aortic prosthesis in a custom-made conduit (1
patient), prosthetic valve endocarditis (1 patient), structural
valve deterioration (1 patient), and end-stage heart failure
(heart transplant) (1 patient). All 6 patients survived reoper-
ation. The freedom from reoperation at 1, 5, and 10 years
was 100%, 96.4%6 2.4%, and 85.7%6 6.4%, respectively.
Figure 2 shows the Kaplan–Meier estimates of freedom from
reoperation.
Prosthetic valve endocarditis developed in 3 patients, 2
early and 1 late. Two patients were deemed inoperable and
were managed with antibiotics alone and died. One patient
underwent reoperation and survived. Five patients had major
hemorrhagic complications; 1 patient died. Four patients had
thromboembolic complications (1 stroke and 3 transient is-
chemic attacks). Valve degeneration developed in 2 patients
with bioprosthetic valves (1 patient underwent reoperation
and survived; 1 patient died in heart failure).
At the latest follow-up, 98 patients were alive and without
reoperation, and in the following New York Heart Associa-
tion functional classes: class I (76 patients), class II (17
patients), class III (5 patients), and class I (1 patient).
Eighty-eight patients were free from any valve- or cardiac-
related event.
Discussion
Although aortic root aneurysm and mitral regurgitation
caused by degenerative disease were the most common indi-
cations for combined ARR and MV surgery in this series,
38% of all patients had combined procedures for other pa-
thologies, some as simple as aortic stenosis with mitral regur-
gitation treated with ARR with a pulmonary autograft and
MV repair and others with complex problems, including mul-
tiple previous operations on both valves, aortic root abscess
Figure 2. Kaplan–Meier estimates of freedom from reoperation
after combined ARR and MV surgery.racic and Cardiovascular Surgery c Volume 136, Number 1 85
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fication of the mitral annulus with porcelain aortic root. Patch
enlargement of the aortic annulus (4 Konno and 12 Manou-
guian procedures) had been performed in 16 patients, and
the aortic root was so deformed at the time of reoperation
that ARR was deemed appropriate. Five patients in this series
had ARR because of a small aortic annulus. We have found
ARR to be a better alternative than patch enlargement of the
fibrous aortic annulus, particularly when the Medtronic Free-
style bioprosthesis (Medtronic Inc, Minneapolis, Minn) is
used because it can be upsized. This variety of pathologies
and the relatively small sample size of this series make
assessment of operative risk and long-term results in the
subgroups of patients with more complex aortic and MV
disorders difficult.
It is clear that first-time ARR combined with MV repair or
replacement is a safe operation and associated with a rela-
tively low operative mortality (there were 2 deaths among
59 patients, for an operative mortality of 3.4%). The opera-
tive mortality for patients who underwent previous cardiac
surgery was higher at 9.4%, although the difference did not
reach statistical significance because of sample size. The low-
est mortality occurred in patients who had first-time aortic
valve sparing combined withMV repair, and the highest mor-
tality was among patients who underwent previous opera-
tions on both valves and required complex reconstruction
of the mitral annulus or aortic root.
Reexploration of the mediastinum for bleeding and im-
plantation of pacemaker for heart block were the most com-
mon postoperative complications. Although most patients
received an antifibrinolytic agent (tranexaminic acid or apro-
tinin), coagulopathy was still common, and 79% required
blood transfusion and 32% required fresh-frozen plasma
and platelets. This was undoubtedly due to long cardiopul-
monary bypass times and continued suction of blood from
the pericardial cavity. Another common postoperative com-
plication was heart block in patients who had previous oper-
ations and required complex reconstruction of the aortic root.
The addition of MV surgery to ARR requires a longer and
more complex operation, but it does not seem to increase op-
erative mortality. In a report by Gott and associates2 on the
clinical outcomes of ARR on 271 patients with Marfan syn-
drome, combined MV surgery was necessary in 40 patients.
There was no death among those 40 patients, and only ad-
vanced functional class and urgent surgery were predictors
of early and late deaths in that series of 271 patients. On
the other hand, Zehr and colleagues6 found that MV disease
was an independent predictor of late death among 203 pa-
tients who had ARR, but only 13 patients had moderate or se-
vere mitral regurgitation. As in Zehr and colleagues’ series,
most other reports on the clinical outcomes of ARR have
a small number of patients with MV disease among those
who underwent ARR.7,8 In a recent report from our institu-
tion on the outcomes of 452 patients who underwent ARR,86 The Journal of Thoracic and Cardiovascular Surgery c July34 (8%) had MV disease.11 MV disease had no effect on op-
erative mortality or long-term survival in that study.11 The
relatively high proportion of patients with MV disease in
Gott and associates’ series of ARR was because all patients
had Marfan syndrome, in whom mitral regurgitation caused
by degenerative disease is common.2 Byrne and colleagues3
found that the operative mortality for ARR was higher in pa-
tients who required coronary artery bypass surgery than in
those who did not (21% vs 0.4%), not necessarily because
of the presence of coronary artery disease but because bypass
surgery may be necessary in patients with more complex aor-
tic root pathology or when technical problems with reimplan-
tation of the right coronary artery occur. Coronary artery
disease was an independent predictor of late deaths in a series
of 452 patients who underwent ARR in our institution.11 Pa-
tients with dysfunctional bicuspid aortic valve may require
ARR, and because the right coronary artery is frequently non-
dominant, right ventricular protection during aortic clamping
may be troublesome, which may have been the cause of
operative death in 2 patients in the present series.
Crawford and Coselli4 reported on 6 patients with Marfan
syndrome who had successful combined ARR and MV re-
placement. Those surgeons replaced the MV through the aor-
tic root. Other surgeons have also used this surgical approach
to repair the MV at the time of aortic valve-sparing operation
or ARR.5,12
There have been case reports of patients with aortic root
aneurysm in whom mitral regurgitation developed because
of distortion of the anterior leaflet of the MV.13,14 In the pres-
ent series, all patients had intrinsic MV disease (Table 2).
The 10-year survival in our series of combined ARR with
MV surgery was 79%. This long-term survival is similar to
those reported for ARR for aneurysms of the aortic root
and other pathologies.2,6,8,11 Gott and colleagues’ series2 of
ARR in patients with Marfan syndrome showed a 10-year
survival of 81%, Zehr and colleagues’ series6 showed a 10-
year survival of 79%, and our series of 452 patients showed
a 10-year survival of 74%.11 Thus, the addition of MV sur-
gery does not seem to worsen the long-term survival.
Reoperations were performed in 6 patients in our series of
123 patients who had combined ARR with MV surgery. Two
patients underwent aortic valve replacement for failed aortic
root remodeling; 1 patient underwent repair of prosthetic aor-
tic valve dehiscence in a custom-made conduit; 1 patient un-
derwent aortic valve replacement for failed bioprosthetic
aortic valve in a custom-made conduit, 1 patient underwent
ARR with aortic homograft and MV replacement for pros-
thetic valve endocarditis, and 1 patient underwent heart
transplantation for end-stage heart failure. All patients sur-
vived reoperations. Valve-related complications (2 prosthetic
valve endocarditis and 1 bioprosthetic valve failure) devel-
oped in 3 additional patients, which could have beenmanaged
surgically but were deemed inoperable because of several
comorbidities.2008
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tion-related hemorrhage and thromboembolic complications,
were similar to those reported for patients with prosthetic
valves.
Conclusions
The degree of complexity of combined ARR with MV sur-
gery varies widely depending on the underlying pathology,
but the operative mortality is reasonably low even in complex
cases, and the long-term survival and clinical outcomes are
excellent.
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